JAK2-IN-14
JAK2-IN-14 is an orally active JAK2 inhibitor with an IC50 of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over JAK1, JAK3, and TYK2, respectively. JAK2-IN-14 inhibits STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3087335-24-5
- Formule: C26H33N7O
- Masse moléculaire:459.59
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
JAK2 2 nM (IC50) |
JAK1 179 nM (IC50) |
JAK3 161 nM (IC50) |
Tyk2 102 nM (IC50) |
STAT5 |
In Vitro
JAK2-IN-14 (Compound 15au) (0.01-5 μM, 24 h) significantly induces cell cycle arrest at the G2/M phase and cell apoptosis in a dose-dependent manner in BaF3-JAK2V617F and HEL cells[1].
JAK2-IN-14 (0.05-1 μM, 2 h) effectively inhibits the phosphorylation of JAK2 and its downstream signaling molecule STAT5 in BaF3-JAK2V617F and HEL cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BaF3-JAK2V617F and HEL cells
-
Concentration:10, 50, 100, 500 and 1000 nM
-
Incubation Time:24 h
-
Result:Blocked the progression of tumor cells at the G2/M phase, leading to a decrease in the proportions of cells in the G1/G0 and G2 phases.
-
Cell Line:BaF3-JAK2V617F and HEL cells
-
Concentration:10, 50, 100, 500 and 1000 nM
-
Incubation Time:2 h
-
Result:Reduced p-JAK2 and p-STAT5 levels concentration-dependently.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | T1/2 | CL/F | AUC0-t |
|---|---|---|---|---|---|---|---|
| Mice[1] | 5 mg/kg | p.o. | 2101.0 ng/mL | 1.0 h | 7.8 h | 1.0 L/h/kg | 5069.7 ng·h/mL |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BaF3-JAK2V617F allogeneic transplantation model established in BALB/c-nude mice[1]
-
Dosage:7.5, 15 and 30 mg/kg
-
Administration:Oral administration (p.o.), once daily for 13 days
-
Result:Demonstrated significant therapeutic efficacy, reducing spleen weight by 24.1%, 26.4%, and 40.5% at doses of 7.5, 15, and 30 mg/kg, respectively
-
Animal Model:HEL cells xenograft model was established in 6-week-old male BALB/c nude mice[1]
-
Dosage:20 and 40 mg/kg
-
Administration:Oral administration (p.o.), once daily for 28 days
-
Result:Significantly inhibited subcutaneous tumor growth.
did not induce observable body weight loss during the experimental period.
Chemical Information
-
CAS No. 3087335-24-5
-
Masse moléculaire 459.59
-
Formule C26H33N7O
-
SMILES
CC1=CN=C(NC2=CC=C(N3CCN(CC4CC4)CC3)C5=C2)N=C1C6=CN(CCCCO5)N=C6
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)